Diabetic enteropathy occurs in many patients with diabetes mellitus. Sialoglycoconjugates play an important role in ensuring normal intestinal function. Tocopherols exert protective effects on the intestinal barrier function. The aim of the study was to comparatively investigate the effect of α-tocopherol on the metabolic parameters of sialoglycoconjugates of the small intestinal wall of rats with alloxan-induced diabetes mellitus. Material and Methods. The study was performed on mongrel male albino rats weighing 180-220 g. The animals were divided randomly into control (I) and experimental (II, III) groups. In rats of groups II and III experimental diabetes mellitus was induced by subcutaneous single injection of alloxan tetrahydrate (170 mg/kg body weight). Group III rats (SD+E) received per os α-tocopherol (2 mg/100 g body weight) daily from days 4 to 40 of the experiments after induction of diabetes. Biological material was collected from all animals. Blood plasma glucose content was studied to control the development of alloxan diabetes, and the levels of free, oligo- and protein-bound sialic acids and sialidase activity were examined in the small intestine wall on days 5, 10, 20, 30 and 40 of the experiments. Results. The study revealed changes in the rate of metabolism of sialoglycoconjugates of the small intestine wall of animals with alloxan diabetes mellitus, which may be associated with changes in metabolism in these cells for adaptation of the rat organism at prolonged increase in blood plasma glucose content on the background of hypoinsulinaemia. When α-tocopherol was administered, a decrease in the level of all studied sialic acid fractions in the wall of small intestine in experimental rats by the end of the experiment was observed. Conclusion. The application of tocopherol had a positive effect on the studied metabolic disorders caused by the development of alloxan diabetes mellitus, which led to a decrease in the changes of sialoglycoconjugate metabolism parameters in the wall of the small intestine of rats.
sialic acids; sialoglycoconjugates; small intestine; tocopherol; alloxan diabetes; sialidase.
1. Dedov I. I., Shestakova M. V., Vikulova O. K., Zheleznyakova A. V., Isakov M. A. Epidemiologicheskie harakteristiki saharnogo diabeta v Rossiyskoy Federacii: kliniko-statisticheskiy analiz po dannym
2. Ibragimova L. I., Kolpakova E. A., Dzagahova A. V., Egshatyan L. V., Pokrovskaya E. V., Derevyanko O. S., Nikonova T. V. Rol' mikrobioty kishechnika v razvitii saharnogo diabeta 1 tipa. Saharnyy diabet.
3. Pavlenko O. A., Trynchenkova N. N., Vorozhcova I. N., Oleynik O. A., Samoylova Yu. G., Harahulah M. I. Mehanizmy vliyaniya rebamipida v terapii hronicheskogo erozivnogo gastrita u bol'nyh saharnym diabetom
4. Fedorchenko Yu. L., Korneeva N. V., Evseev A. N., Martynyuk M. V. Zabolevaniya verhnih otdelov zheludochno-kishechnogo trakta u bol'nyh saharnym diabetom. Habarovsk: Izd. DVGU; 2020.
5. Thomas H. Diabetes: Circulating factors implicated in diabetic enteropathy. Nat Rev Endocrinol. 2015;11(12):688. doi:10.1038/ nrendo.2015.184.
6. Vidershayn G. Ya. Glikobiologiya: uspehi, problemy i perspektivy. Biohimiya. 2013;78(7):877-900.
7. Breugelmans T., Oosterlinck B., Arras W., Ceuleers H., De Man J., Hold G. L., De Winter B. Y., Smet A. The role of mucins in gastrointestinal barrier function during health and disease. Lancet Gastroenterol Hepatol.
8. Vol'hina I. V., Butolin E. G. Kliniko diagnosticheskoe znachenie opredeleniya sialovyh kislot v biologicheskih ob'ektah. Biomedicinskaya himiya. 2022;68(1):7-17. doi:10.18097/ PBMC20226801007.
9. Doostkam A., Malekmakan L., Hosseinpour A., Janfeshan S., Roozbeh J., Masjedi F. Sialic acid: an attractive biomarker with promising biomedical applications. Asian Biomed (Res Rev News). 2022 Aug 31;16(4):153-167.
10. Ciarcià G., Bianchi S., Tomasello B., Acquaviva R., Malfa G.A., Naletova I., Mantia A., Di Giacomo C. Vitamin E and Non-Communicable Diseases: A Review. Biomedicines. 2022;10(10):2473.
11. Vincenzo A. D., Tana C., Hadi H., Pagano C., Vettor R., Rossato M. Antioxidant, AntiInflammatory, and Metabolic Properties of Tocopherols and Tocotrienols: Clinical Implications for Vitamin E Supplementation in Diabetic
12. Oladokun O. O., Olaleye T. C., Moses N. M., Oladosu O. A., Babatunde A. A., Adedokun K. I., Owonikoko M. W., Ajeigbe K.O. Tocopherol Enhances the Antioxidant Defense System and Histomorphometric Parameters in The
13. Liu K. Y., Nakatsu C. H., Jones-Hall Y., Kozik A., Jiang Q. Vitamin E alpha- and gamma-tocopherol mitigate colitis, protect intestinal barrier function and modulate the gut microbiota in mice. Free Radic Biol Med. 2021;163:180-
14. Loginov P. V. The effect of vitamin E (α-tocopherol) on functional condition of hypothalamic-pituitary-testicular complex in wistar male rats. Sovremennye naukoemkie tekhnologii. 2005;7:50-51 (in Russ.).
15. El-Aal A. A., El-Ghffar E. A. A., Ghali A. A., Zughbur M. R., Sirdah M. M. The effect of vitamin C and/or E supplementations on type 2 diabetic adult males under metformin treatment: A single-blinded randomized controlled
16. Vol'hina I. V., Butolin E. G. Vliyanie lipoevoy kisloty na obmen sialovyh kislot v stenke tonkoy kishki krys s alloksanovym diabetom. Pediatr. 2020;11(1):37-42. doi:10.17816/ ped11137-42.
17. Savinova N. V., Danilova O.V., Perevedenceva S. E., Trofimova S. R., Naumova N. G. Dinamika metabolizma kollagena v tkanyah krys s eksperimental'nym diabetom, protekayuschim na fone hronicheskogo
18. Voroncova T. S., Vasil'eva N. N., Butolin E. G., Ivanov V. G., Isakova L. S. Vliyanie vraschayuschihsya elektricheskih poley na biopolimery pecheni: eksperimental'noe issledovanie. Ekologiya cheloveka.
19. Jiang M., Li X., Zhang J., Lu Y., Shi Y., Zhu C., Liu Y., Qin B., Luo Z., Du Y., Luo L., Peng L., You J. Dual Inhibition of Endoplasmic Reticulum Stress and Oxidation Stress Manipulates the Polarizationof Macrophages under
20. Schegravina E. S., Sachkova A. A.,Usova S.D.,Nyuchev A. V., Gracheva Yu. A., Fedorov A. Yu. Napravlennaya dostavka s primeneniem uglevodnyh sistem: ozhidaniya i real'nost'.Bioorganicheskaya himiya.2021;47(1):76-105
21. Piccoli M., Coviello S., Canali M.E., Rota P., Rocca P., Cirillo F., Lavota I., Tarantino A., Ciconte G., Pappone C., Ghirildi A., Anastasia L. Neu3 Sialidase Activates the RISK Cardioprotective Signaling Pathway during Ischemia
22. Fougerat A., Pan X., Smutova V., Heveker N., Cairo C. W., Issad T., Larrivée B., Medin J. A., Pshezhetsky A. V. Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice. Mol. Metab.
23. Miyagi T., Yamamoto K. Sialidase NEU3 and its pathological significance. Glycoconj J. 2022;39(5):677-683. doi:https://doi.org/10.1007/s10719-02210067-7.
24. Bozic J., Markotic A., Cikes-Culic V., Novak A., Borovac J.A., Vucemilovic H., Trgo G., Ticinovic K.T. Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: implications
25. Serna I., Beveridge M., Wilke M., Ryan E., Clandinin M., Mazurak V. Interorgan Metabolism of Ganglioside Is Altered in Type 2 Diabetes. Biomedicines. 2022;10(12):3141. doi:10.3390/ biomedicines10123141.
26. Jennemann R., Kaden S., Volz M., Nordström V., Herzer S., Sandhoff R., Gröne H-J. Gangliosides modulate insulin secretion by pancreatic beta cells under glucose stress. Glycobiology. 2020;30(9):722
27. Baud G., Raverdy V., Bonner C., Daoudi M., Caiazzo R., Pattou F. Sodium glucose transport modulation in type 2 diabetes and gastric bypass surgery. Surgery for Obesity and Related Diseases. 2016;12 -(6):1206-1212.
28. Conte M., Cosorich I., Ferrarese R., Cencicchio M., Nobili A., et al. Alterations of the intestinal mucus layer correlate with dysbiosis and immune dysregulation in human Type 1 Diabetes. EBioMedicine. 2023;91:104567.
29. Miyazawa T., Burdeos G., Itaya M., Nakagawa K., Miyazawa T. Vitamin E: Regulatory Redox Interactions. IUBMB Life. 2019;71(4):430441. doihttps://doi.org/10.1002/iub.2008.
